Olr517 inhibitors represent a distinct class of chemical compounds characterized by their ability to modulate the activity of the Olr517 protein. This protein, a member of the olfactory receptor family, is integral to the chemosensory systems in organisms, where it plays a critical role in the detection of chemical stimuli. The inhibition of Olr517 offers a fascinating perspective on understanding the molecular interactions and signaling pathways associated with olfactory receptors. Inhibitors targeting Olr517 typically possess specific structural features that allow them to bind selectively to this protein, thereby preventing it from engaging in its natural ligand interactions. The study of these inhibitors is of particular interest in the field of chemical biology, as they provide insights into the structure-function relationships that govern olfactory receptor activity.
The chemical structure of Olr517 inhibitors often includes heterocyclic frameworks or functional groups that facilitate their binding to the receptor's active site. Advanced techniques such as molecular docking and spectroscopic analyses are employed to explore the binding affinities and conformational changes induced by these inhibitors. Understanding these interactions at a molecular level is essential for unraveling the mechanisms by which Olr517 influences olfactory signal transduction. Additionally, the synthesis and characterization of Olr517 inhibitors contribute to the broader field of receptor biology, where the precise modulation of receptor activity is crucial for dissecting the roles of individual receptors within complex biological systems. Through this lens, Olr517 inhibitors offer a valuable tool for probing the intricate network of molecular signals that underlie the sensory perception of chemical stimuli.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $131.00 $651.00 | 7 | |
An mTOR inhibitor, potentially influencing proteins involved in cell growth and proliferation. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Inhibits EGFR tyrosine kinase, potentially affecting proteins in the EGFR signaling pathway. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Inhibits JAK1/2, potentially affecting proteins in cytokine signaling pathways. | ||||||
Belinostat | 414864-00-9 | sc-269851 sc-269851A | 10 mg 100 mg | $156.00 $572.00 | ||
Inhibits histone deacetylases, potentially affecting gene expression and chromatin remodeling proteins. | ||||||
XL-184 free base | 849217-68-1 | sc-364657 sc-364657A | 5 mg 10 mg | $94.00 $208.00 | 1 | |
Inhibits MET, VEGFR, and RET, potentially affecting proteins in multiple signaling pathways. | ||||||
Ixazomib | 1072833-77-2 | sc-489103 sc-489103A | 10 mg 50 mg | $311.00 $719.00 | ||
Proteasome inhibitor, potentially affecting protein degradation and cell cycle regulation. | ||||||
Lenvatinib | 417716-92-8 | sc-488530 sc-488530A sc-488530B | 5 mg 25 mg 100 mg | $182.00 $661.00 $1690.00 | 3 | |
Targets multiple tyrosine kinases, including VEGFR, potentially affecting angiogenesis-related proteins. | ||||||
Niraparib | 1038915-60-4 | sc-507492 | 10 mg | $150.00 | ||
PARP inhibitor, potentially affecting proteins involved in DNA repair pathways. | ||||||
Osimertinib | 1421373-65-0 | sc-507355 | 5 mg | $86.00 | ||
Targets EGFR with T790M mutation, potentially affecting proteins in mutated EGFR pathways. | ||||||
AP 24534 | 943319-70-8 | sc-362710 sc-362710A | 10 mg 50 mg | $175.00 $983.00 | 2 | |
Multi-targeted tyrosine kinase inhibitor, potentially influencing various cell signaling proteins. | ||||||